Health Canada Authorizes Canada’s First Rapid COVID-19 Antibody Test

 

Canada NewsWire

BARRIE, ON,Feb. 16, 2021/CNW/ – Verify Diagnostics announced today that Health Canada has authorized the Assure Tech Ecotest COVID-19 serological rapid test to be used at the point-of-care (POC) for the purpose of screening for SARS-CoV-2 antibodies. Building on the U.S. FDA Emergency Use Authorization (EUA) granted last year, Verify Diagnostics has worked diligently with Health Canada, sinceMarch 2020, to bring this test toCanada. The Assure Tech Ecotest was the first point-of-care fingerstick blood test to be authorized for CLIA Waived use inthe United Statesand is the first Canadian test to be authorized as well.

The Assure Tech Ecotest is the first rapid test to be authorized by Health Canada for the detection of COVID-19 antibodies. The Ecotest was also the first test to be authorized in the United States for point-of-care testing. (CNW Group/Verify Diagnostics Inc.)

“Antibody testing is key to understanding the prevalence of COVID-19 in our Canadian communities and, although complicated laboratory solutions are available to accomplish this, rapid testing offers an easy and inexpensive option to healthcare professionals and public health organizations.” saidTim Salter, President of Verify Diagnostics. “Use of these rapid tests have been proven effective in dozens of countries that we have provided solutions to and we are very happy to be able to now provide a solution forCanada.”.Verify Diagnostics has promoted the use of antibody tests globally since the beginning of the pandemic as a way to measure the disease’s spread through communities and, more recently, to track the efficacy of vaccination programmes. “One of the unknowns related to SARS-CoV-2 vaccines is how long the immunization will remain effective against the virus.” said Salter. “We hope thatCanadawill follow suit with some of the other governments and organizations that we are working with to monitor those that have received inoculations to better understand how long immunity against the virus will last.”.Appropriate training is also an important factor in ensuring that rapid tests are both used properly and interpreted correctly. “We have invested significant resources into creating multilingual online courses for all of the testing solutions we offer, including COVID-19 tests.” said Salter. “There’s a difference between selling a product and providing a solution, we have always focussed on the latter.”.About Verify DiagnosticsBased inBarrie, Ontario, CanadaVerify Diagnostics is focussed on delivering innovative point-of-care solutions with specialities in drugs of abuse, fertility and infectious disease testing.

Verify Diagnostics is a Canadian leader in diagnostic testing with specialties in drugs of abuse, fertility and infectious disease testing. (CNW Group/Verify Diagnostics Inc.)

SOURCE Verify Diagnostics Inc.CisionView original content to download multimedia:http://www.newswire.ca/en/releases/archive/February2021/16/c5919.html